newsfilter
← Latest News
GlobeNewswire·

OnKure Therapeutics Reports First Quarter 2026 Financial Results

-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company's pipeline in vascular